SG11202000115SA - Novel therapeutic enzyme fusion protein and use thereof - Google Patents

Novel therapeutic enzyme fusion protein and use thereof

Info

Publication number
SG11202000115SA
SG11202000115SA SG11202000115SA SG11202000115SA SG11202000115SA SG 11202000115S A SG11202000115S A SG 11202000115SA SG 11202000115S A SG11202000115S A SG 11202000115SA SG 11202000115S A SG11202000115S A SG 11202000115SA SG 11202000115S A SG11202000115S A SG 11202000115SA
Authority
SG
Singapore
Prior art keywords
fusion protein
therapeutic enzyme
novel therapeutic
enzyme fusion
novel
Prior art date
Application number
SG11202000115SA
Inventor
Yong Ho Heo
Jin Young Kim
In Young Choi
Sung Youb Jung
Original Assignee
Hanmi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharmaceutical Co Ltd filed Critical Hanmi Pharmaceutical Co Ltd
Publication of SG11202000115SA publication Critical patent/SG11202000115SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/528—CH4 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06001—Arylsulfatase (3.1.6.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06012—N-Acetylgalactosamine-4-sulfatase (3.1.6.12)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)

Abstract

NOVEL THERAPEUTIC ENZYME FUSION PROTEIN AND USE THEREOF [] The present invention relates to a fusion protein between a therapeutic enzyme and an immunoglobulin Fc region, a method thereof, and a composition comprising the fusion protein. [FIG. 1]
SG11202000115SA 2017-07-07 2018-07-09 Novel therapeutic enzyme fusion protein and use thereof SG11202000115SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20170086594 2017-07-07
PCT/KR2018/007754 WO2019009684A2 (en) 2017-07-07 2018-07-09 Novel therapeutic enzyme fusion protein and use thereof

Publications (1)

Publication Number Publication Date
SG11202000115SA true SG11202000115SA (en) 2020-02-27

Family

ID=64950229

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202000115SA SG11202000115SA (en) 2017-07-07 2018-07-09 Novel therapeutic enzyme fusion protein and use thereof

Country Status (16)

Country Link
US (1) US20200157172A1 (en)
EP (1) EP3650539A4 (en)
JP (2) JP2020530283A (en)
KR (2) KR102413686B1 (en)
CN (1) CN111094559A (en)
AR (1) AR112755A1 (en)
AU (1) AU2018295994A1 (en)
BR (1) BR112020000273A2 (en)
CA (1) CA3069119A1 (en)
EA (1) EA202090084A1 (en)
IL (1) IL271837B2 (en)
MX (1) MX2020000037A (en)
PH (1) PH12020500054A1 (en)
SG (1) SG11202000115SA (en)
WO (1) WO2019009684A2 (en)
ZA (1) ZA202000595B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019070577A1 (en) 2017-10-02 2019-04-11 Denali Therapeutics Inc. Fusion proteins comprising enzyme replacement therapy enzymes
KR102588611B1 (en) * 2017-12-22 2023-10-16 한미약품 주식회사 Therapeutic enzyme fusion protein having a novel structure and use thereof
KR20230086703A (en) 2020-10-14 2023-06-15 데날리 테라퓨틱스 인크. Fusion protein containing sulfoglucosamine sulfohydrolase enzyme and method thereof
IL302858A (en) * 2020-11-13 2023-07-01 Hanmi Pharm Ind Co Ltd Use of therapeutic enzyme fusion protein in prevention and treatment of renal diseases caused by or accompanied by fabry disease
US20230416714A1 (en) * 2020-11-13 2023-12-28 Hanmi Pharm. Co., Ltd Use of therapeutic enzyme fusion protein in prevention and treatment of neuropathy caused by or accompanied by fabry disease

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0136514B1 (en) * 1994-12-23 1998-07-01 양승택 Speed matching device of common line signal device
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
MXPA03006294A (en) * 2001-01-18 2003-09-16 Merck Patent Gmbh Bifunctional fusion proteins with glucocerebrosidase activity.
MXPA03008031A (en) * 2001-03-07 2003-12-04 Merck Patent Gmbh Expression technology for proteins containing a hybrid isotype antibody moiety.
JP2009521912A (en) * 2005-12-30 2009-06-11 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Anti-CD19 antibody with reduced immunogenicity
WO2008087184A2 (en) * 2007-01-17 2008-07-24 Merck Serono S.A. Process for the purification of fc-containing proteins
US9657105B2 (en) * 2013-03-15 2017-05-23 City Of Hope CD123-specific chimeric antigen receptor redirected T cells and methods of their use
KR20210130260A (en) * 2013-04-02 2021-10-29 추가이 세이야쿠 가부시키가이샤 Fc region variant
KR101895634B1 (en) * 2013-05-31 2018-09-05 한미약품 주식회사 IgG4 Fc fragment comprising modified hinge region
WO2015009052A1 (en) * 2013-07-16 2015-01-22 일동제약 주식회사 Fusion protein of immunoglobulin hybrid fc and enzyme
KR20230141929A (en) * 2013-07-31 2023-10-10 암젠 인크 Stabilization of fc-containing polypeptides
MX2016005687A (en) * 2013-10-30 2017-03-30 Genzyme Corp Methods for enhancing immunosuppressive therapy by multiple administration of alpha beta tcr-binding polypeptide.
MX2018004177A (en) * 2015-10-08 2018-09-11 Macrogenics Inc Combination therapy for the treatment of cancer.
AU2016365834B2 (en) * 2015-12-08 2023-09-28 Regeneron Pharmaceuticals, Inc. Compositions and methods for internalizing enzymes
AR107483A1 (en) * 2016-01-29 2018-05-02 Hanmi Pharm Ind Co Ltd CONJUGATE OF THERAPEUTIC ENZYMES

Also Published As

Publication number Publication date
CN111094559A (en) 2020-05-01
EA202090084A1 (en) 2020-06-19
MX2020000037A (en) 2020-08-06
KR20190005803A (en) 2019-01-16
KR102413686B1 (en) 2022-06-28
KR102556411B1 (en) 2023-07-18
EP3650539A2 (en) 2020-05-13
JP2023085445A (en) 2023-06-20
US20200157172A1 (en) 2020-05-21
JP2020530283A (en) 2020-10-22
BR112020000273A2 (en) 2020-07-14
EP3650539A4 (en) 2021-08-18
WO2019009684A2 (en) 2019-01-10
CA3069119A1 (en) 2019-01-10
AU2018295994A1 (en) 2020-02-06
KR20220098092A (en) 2022-07-11
ZA202000595B (en) 2021-04-28
IL271837B2 (en) 2024-01-01
IL271837B1 (en) 2023-09-01
TW201906872A (en) 2019-02-16
WO2019009684A3 (en) 2019-03-28
AR112755A1 (en) 2019-12-11
IL271837A (en) 2020-02-27
PH12020500054A1 (en) 2020-09-21

Similar Documents

Publication Publication Date Title
SG11202000115SA (en) Novel therapeutic enzyme fusion protein and use thereof
MX2020006322A (en) Engineered il-2 fc fusion proteins.
EP3788068A4 (en) Interleukin 15 fusion proteins, and compositions and therapeutic methods thereof
PH12018502361A1 (en) Gdf15 fusion proteins and uses thereof
PH12020550927A1 (en) Therapeutic enzyme fusion protein having novel structure and use thereof
WO2018109170A3 (en) Il-11ra antibodies
MA50746A (en) FUSION PROTEINS INCLUDING SUBSTITUTIVE ENZYMOTHERAPY ENZYMES
MY180831A (en) Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use
SG10201909716RA (en) Modified j-chain
SG11201806502UA (en) Conjugate of therapeutic enzymes
EP3749683A4 (en) Fgf21 variant, fusion protein and application thereof
MY187827A (en) New polypeptide having affinity to pd-l1
EP3626747A4 (en) Novel recombinant bifunctional fusion protein, preparation method therefor and use thereof
EP3735458A4 (en) Recombinant human sialidases, sialidase fusion proteins, and methods of using the same
MX2020005170A (en) Vegfr-fc fusion protein formulations.
EP3842536A4 (en) Immunoglobulin-binding protein, and affinity carrier using same
WO2018183182A8 (en) Methods and compositions for reduction of immunogenicity
EP3833391A4 (en) SIRP1alpha TARGETED CHIMERIC PROTEINS AND USES THEREOF
SG10201801219VA (en) Anti-HER2 Antibodies
MX2017010359A (en) Fc-FUSED HIGH AFFINITY IgE RECEPTOR a-CHAIN.
EP3976642A4 (en) Apoe antibodies, fusion proteins and uses thereof
EP3604343A4 (en) Fusion protein, preparation method therefor and use thereof
EP3995508A4 (en) Novel modified immunoglobulin fc-fusion protein and use thereof
EP3950720A4 (en) Fusion protein and use thereof
WO2020123330A3 (en) Anti-alpha-synuclein antibodies and uses thereof